United States · Investor

Red Abbey Venture Partners

Last cheque observed Jun 2015. Silence since then is not evidence of inactivity: our sources miss unannounced rounds.

QuietVC firm

Series CSeedSeries AFamilySocial Network

Cheques on record
0%of best year0cheques in 12 months, 12 on record
Since the last cheque4137days00hrs00min00sec
Median round$19MRounds led0 of 12Exits3 from the portfolioMostly inUnited States, 89%
Pitch Red Abbey Venture Partners

Red Abbey Venture Partners highlights

  1. 01

    12 rounds on record

  2. 02

    Mostly Series C and Seed: 58% of its rounds

  3. 03

    3 exits from the portfolio

What they do

Type
VC firm (from a list, unverified)
Cheque size
Not stated
Sectors
FamilySocial Network
Based in
United States
Cold pitches
Not stated

The record

Every round we can evidence, newest first12 appearances

  1. 2015

    1 round

  2. Jun
    Cohero HealthSeed$2.0MWith 7 others
  3. 2010

    1 round

  4. Jun
    Corridor PharmaceuticalsSeries A · US · finance.yahoo.com$13MWith 7 others
  5. 2009

    2 rounds

  6. Nov
    OxagenSeries C · GB · fiercebiotech.com$27MWith 8 others
  7. Oct
    Corridor PharmaceuticalsSeries A · US · venturedeal.com$11MWith 3 others
  8. 2008

    3 rounds

  9. Oct
    Seed · findarticles.com$2.3MWith 3 others
  10. Oct
    Corridor PharmaceuticalsSeed · US · findarticles.com$2.3MWith 3 others
  11. Apr
    StromedixSeries B · US$25MWith 4 others
  12. 2007

    1 round

  13. Feb
    Advanced BioHealingSeries C · US · abh.com$26MWith 4 others
  14. 2006

    2 rounds

  15. Aug
    Series A · highbeam.com$4.5MWith 20 others
  16. May
    MacroGenicsSeries C · US · macrogenics.com$45MWith 10 others
  17. 2005

    2 rounds

  18. Oct
    Nereus PharmaceuticalsSeries D · US$43MWith 11 others
  19. May
    Anacor PharmaceuticalSeries C · US · anacor.com$25MWith 4 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

The team

We hold 2 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

Exits from the portfolio

Companies it backed that were later bought or listed3 in all

StromedixBought by Biogen Idec$750MFeb 2014
Advanced BioHealingBought by Shire$750MMay 2011
Anacor PharmaceuticalListedUndisclosedDec 2010

An exit counts when it came after the firm's first round in the company. From historical deal records.

Who they invest alongside

The investors most often in the same rounds as Red Abbey Venture Partners. A count of rooms they were both in, not a relationship either has claimed.

Quick answers about Red Abbey Venture Partners

What does Red Abbey Venture Partners invest in?

Red Abbey Venture Partners invests most often at Series C and Seed (58% of the rounds on record), in sectors such as Family and Social Network.

How active is Red Abbey Venture Partners?

12 investments on record, 0 of them in the last 12 months. The most recent was in Jun 2015.

How big are Red Abbey Venture Partners's cheques?

The median round it joins is $19M.

Does Red Abbey Venture Partners lead rounds?

Rarely, if at all: none of its 12 investments on record names it as the lead.

Where does Red Abbey Venture Partners invest?

Most of the companies it backs are in the United States (89%) and the United Kingdom (11%).

Is Red Abbey Venture Partners investing now?

No investments in the last 12 months; the latest was in Jun 2015.

Who does Red Abbey Venture Partners invest alongside?

Most often MedImmune Ventures (5 rounds together), Quaker Partners (5 rounds together) and Acidophil (4 rounds together).

What kind of investor is Red Abbey Venture Partners?

Red Abbey Venture Partners is a VC firm based in United States.

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it